SUSTOVA
Testosterone Blend 250 mg/ml injection for HRT, vitality, muscle support, and hormone balance.
CAS Number: 58-22-0
SUSTOVA is indicated for males with testosterone deficiency, supporting balanced hormone levels, improved physical and metabolic function, and addressing symptoms such as fatigue, reduced libido, and muscle loss. Used under professional supervision for HRT and stable testosterone maintenance.
SUSTOVA by Nova Techsciences is presented as a testosterone blend injectable with a stated strength of 250 mg/ml. The product information associates the formulation with CAS Number 58-22-0. This CAS number identifies testosterone, the parent hormone, rather than every possible testosterone ester that may be included in a blended formulation. For complete accuracy, the website, vial label and Certificate of Analysis should identify each testosterone component and its individual concentration.
This page provides neutral product-identification, quality and safety information. It does not replace an authorised Summary of Product Characteristics, patient information leaflet or advice from a qualified healthcare professional.
SUSTOVA Product Overview
Important product details include:
- Product name: SUSTOVA
- Product category: Testosterone blend injectable
- Stated strength: 250 mg/ml
- Parent-compound CAS Number: 58-22-0
- Brand: Nova Techsciences
When a medicine contains esterified forms of testosterone, accurate documentation should distinguish the parent hormone from each ester used in the finished formulation. The complete composition, excipients, administration route, storage conditions, batch number, manufacturing date and expiry date should appear consistently across the label, packaging and official product records.
Quality Control and Traceability
Injectable formulations require controlled manufacturing and documented quality assessment. Relevant records may include raw-material identity testing, active-compound assay, impurity analysis, sterility testing, microbiological controls, particulate assessment and container-closure integrity.
Every SUSTOVA batch should carry a unique batch number linked to production and laboratory records. Claims regarding purity, pharmaceutical quality or manufacturing standards should only be published when current evidence is available. Clear traceability also helps healthcare professionals and regulatory reviewers confirm that the product information matches the batch being evaluated.
For the United Kingdom and the Netherlands, the page should state whether the product holds the required marketing authorisation. The MHRA regulates medicines in the UK, while the Medicines Evaluation Board evaluates and registers medicines in the Netherlands.
Important Safety Information
Testosterone belongs to the anabolic-androgenic steroid class. In the UK, anabolic steroids are prescription-only medicines, and non-medical use may lead to serious side effects and dependence. Potential concerns can include hormonal disruption, fertility changes, altered cholesterol, cardiovascular complications, mood changes and injection-related problems.
SUSTOVA should not be presented for self-medication, use by minors or unsupervised performance enhancement. Dosage schedules, injection techniques, cycles and product combinations should not be taken from unofficial online sources. Any lawful medical use requires individual assessment and ongoing monitoring by an appropriately qualified healthcare professional.
Related Nova Techsciences Products
TESTOVA P
TESTOVA P is another Nova Techsciences testosterone injectable. Its product page should clearly distinguish its testosterone ester, stated concentration, CAS information, storage requirements and monitoring considerations from the multi-component SUSTOVA formulation.
NANDROVA D
NANDROVA D belongs to the nandrolone product range and is chemically different from testosterone-based formulations. Its supporting information should cover the exact compound identity, strength, batch testing, contraindications and applicable legal supply status.
TRENOVA E
TRENOVA E is listed within the trenbolone injectable range. Because trenbolone compounds are distinct from testosterone medicines, its page should use carefully verified CAS data, clear risk communication, traceable laboratory documentation and prominent warnings against unsupervised use.
NANDROVA P
NANDROVA P is a separate nandrolone formulation from NANDROVA D. Its ester identity, product strength, quality records and safety information should be presented independently, since products within the same compound family are not automatically interchangeable.
SUSTOVA should ultimately be presented through accurate composition, transparent batch documentation, balanced safety information and clearly stated regulatory status. This approach creates a more trustworthy product page for healthcare professionals, distributors and regulatory reviewers in European markets.
Important Information & FAQs
Precautions & Contraindications
Precautions
- Use strictly under medical supervision.
- Follow prescribed dosage.
- Do not self-medicate.
- Inform your doctor of all medications or supplements.
- Monitor for unusual reactions like swelling, mood changes, or injection-site issues.
- Keep out of reach of children.
Contraindications
- Do not use if allergic to testosterone or any ingredient.
- Not for individuals with prostate cancer, severe heart disease, or untreated sleep apnea.
- Pregnant or breastfeeding women must not use.
- Regular medical monitoring is recommended for hormone levels and liver function.
Related Products
BOLDENOVA
Boldenone Undecylenate 250 mg/ml injection for lean bulking, endurance, and performance enhancement.
DROSTANOVA P
Dry, anti-estrogenic Drostanolone Propionate 100 mg/ml injectable for cutting, muscle hardening, and strength enhancement.
NANDROVA D
Nandrolone Decanoate 250 mg/ml injection for lean bulking, recovery, and joint support.
NANDROVA P
Fast-acting Nandrolone Phenylpropionate 100 mg/ml injection for muscle recovery, nitrogen retention, and rehabilitation.